INC makes key Japanese appoitnments
This article was originally published in Scrip
Clinical research organization INC Research has made three key management appointments in Japan. Hiromi Wakita has been named general manager and clinical director, leading the firm's operations in Japan. He joins INC from previous positions in both pharmaceutical companies and other CRO firms. Hiroshi Uoji has also joined the company as regulatory and safety director for Japan. Finally INC has named Shinichi Sato project director, CNS clinical development in Japan. All three new appointees will be based in the firm's Tokyo Office.
You may also be interested in...
Angeli Möller, recently spotlighted by In Vivo as a 2020 Rising Leader, has quickly moved up the ranks at Bayer and is now spearheading one of its key initiatives to bring artificial intelligence and machine learning technologies into the pharma business.
Coaching and mentoring are important tools for the leaders of today to be able to foster the next generation of talent in the biopharma sector. While the routes into industry have not changed dramatically – most leaders hold a master’s degree and/or PhD – the expectations of rising leaders have altered and the industry itself has become more collaborative.
In this first edition of In Vivo's ‘Rising Leaders’ list, the focus is on entrepreneurs and innovators who represent the next wave of creativity in health care.